Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Recombinant BCG85C5 vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 30/September/2020, 23.58

Trimtone Fat Burner For Women That Really Works
September 23, 2020
PTC299-based therapy for COVID-19/SARS-COV-2 and other infectious diseases: PTC299, an anti-cancer drug, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines 24/October/2020, 9.39 am
October 24, 2020
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33), by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Recombinant BCG85C5 vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 30/September/2020, 23.58


What is known?

Prof. Stephen Elledgeresearch team has showed thatinterferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

This study suggests, for the first time, that recombinant Bacillus Calmette Guerin (BCG) vaccine-based therapy, with detailed mechanistic insights, for COVID-19 and other infectious diseases. Recombinant BCG 85C5 vaccine, by increasing the expression of its target genes, it may increase the expression of TLR2, MHCII, IL-12, STAT1/2, IRF9/3, IFITM3/1, Interferon-alpha/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3/1, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides. Thereby, it may: (1) inhibit the replication of  SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figure 1) Thus, pharmacological formulations encompassing “recombinant BCG85C5 vaccine, either alone or in combination with other drugs, can be used to prevent/treat/protect against infections caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses (Figure 2).

Figure 1 Mechanistic insight into how recombinant BCG85C5 vaccine protects against a number of infectious diseases. Recombinant BCG85C5 vaccine protects against SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial , Sindbis, and SFV viruses production through induction of its target genes, such as antiviral Proteins STAT1/2, IRF9/3, IFITM3/1, Interfern-alpha/beta/gamma/lamda, Interferon-stimulated gene 15, Mx2 and others
Figure 2 What constitutes recombinant BCG85C5 vaccine; and how it protects against a number of infectious diseases.
Figure 3.  Recombinant TB/BCG85C5 vaccine can function as a broad-spectrum anti-infective agent.
Figure 4.  Recombinant TB/BCG85C5 vaccine can prevent/treat/protect against SARS-COV-2.
This image has an empty alt attribute; its file name is BCG-Vaccine-aids-in-attenuation-of-SARS-coronavirus2-SARS-COV2-production-and-can-protect-against-SARS-COV2-infection.jpg5_-770x578.jpg
Figure 5.  Repurposing the recombinant TB/BCG85C5 into a SARS-COV-2 vaccine. GBMD (genomediscovery.org) is looking for collaborators who wish to take it to the next stage.

Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How turberculosis recombinant TB/BCG85C5  increases the expression of antiviral Protein IFITM3, Interferon-stimulated gene 15, & Mx2

Type: Research cooperation

For more details on research cooperation, you may reach us at drboomi@genomediscovery.org or admin@genomediscovery.org


References: 

CitationBoominathan L, Repurposing the tuberculosis BCG vaccine into a Prophylactic COVID-19 vaccine: Recombinant BCG85C5 vaccine inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 30/September/2020, 23.58

Courtesy: When you cite drop us a line at info@genomediscovery.org,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.